RedHill Biopharma Presents Business Update at Sachs Forum

Ticker: RDHL · Form: 6-K · Filed: Feb 27, 2025 · CIK: 1553846

Redhill Biopharma Ltd. 6-K Filing Summary
FieldDetail
CompanyRedhill Biopharma Ltd. (RDHL)
Form Type6-K
Filed DateFeb 27, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: business-update, filing, life-sciences

TL;DR

RedHill gave a business update at a Sachs forum, filing it with the SEC.

AI Summary

RedHill Biopharma Ltd. filed a Form 6-K on February 27, 2025, to report a business update presented at the Sachs European Life Sciences CEO Forum. The filing incorporates by reference a press release detailing this update, which is intended to be included in the company's existing SEC registration statements.

Why It Matters

This filing signals ongoing communication with investors and the life sciences community regarding RedHill's business progress and strategic initiatives.

Risk Assessment

Risk Level: low — This is a routine filing reporting on a presentation, not a material event like a financing or clinical trial result.

Key Players & Entities

  • RedHill Biopharma Ltd. (company) — Registrant
  • Sachs (company) — Organizer of the European Life Sciences CEO Forum
  • February 2025 (date) — Reporting period for the Form 6-K
  • 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (address) — Principal executive offices

FAQ

What is the purpose of this Form 6-K filing?

The purpose of this Form 6-K is to report a business update presented by RedHill Biopharma Ltd. at the Sachs European Life Sciences CEO Forum, incorporating the related press release by reference.

When was this Form 6-K filed?

This Form 6-K was filed on February 27, 2025.

What event did RedHill Biopharma present at?

RedHill Biopharma presented at the Sachs European Life Sciences CEO Forum.

Where are RedHill Biopharma's principal executive offices located?

RedHill Biopharma's principal executive offices are located at 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel.

Does this filing update any existing SEC registration statements?

Yes, this Form 6-K is incorporated by reference into the Company's existing Registration Statements on Form S-8.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on February 27, 2025 regarding RedHill Biopharma Ltd. (RDHL).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.